

# Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients

NCT03695978

---

**Status** RECRUITING  
**Sponsor** Octapharma  
**Enrollment** 200 participants

## Key Eligibility Criteria

---

### Inclusion (10)

- Male and female patients of any age and ethnicity
- Severe haemophilia A (FVIII:C<1%)
- Decision to prescribe Octapharma's FVIII concentrate before enrollment into the study
- Either
- No previous treatment with FVIII concentrates or other blood products containing FVIII (PUPs) OR
- ... and 5 more (see full listing online)

### Exclusion (4)

- Diagnosis with a coagulation disorder other than haemophilia A
- Concomitant treatment with any systemic immunosuppressive drug
- Participation in an interventional clinical trial during the time period evaluated
- Participation in another non-interventional study of Octapharma

## Locations (55 total)

---

University of Miami Miller School of Medicine, Miami, Florida, United States  
Ochsner Clinic Foundation, New Orleans, Louisiana, United States  
Cure 4 The Kids Foundation Children's Specialty Center, Las Vegas, Nevada, United States  
... and 52 more locations